文献速递复苏、休克与脓毒症创伤与烧伤重症综合管理与镇静镇痛

黏弹性止血检测增强的大出血方案用于严重创伤出血(ITACTIC):一项随机对照试验

Viscoelastic haemostatic assay augmented protocols for major trauma haemorrhage (ITACTIC): a randomized, controlled trial.
PubMed 文献 · Intensive Care Med · 2020-10-13
一句话结论在严重创伤大出血中,用黏弹性止血检测(VHA)增强大出血方案相比传统凝血检测(CCT)并未改善24小时无大量输血生存率或28天死亡率。

ITACTIC是一项多中心随机对照试验,纳入396例接受经验性大出血方案的创伤患者,比较VHA增强方案(201例)与CCT增强方案(195例)的效果。主要终点为伤后24小时存活且无需大量输血(≥10单位红细胞)的比例,VHA组67% vs CCT组64%(OR 1.15,95%CI 0.76-1.73),无显著差异。28天死亡率VHA组25% vs CCT组28%(OR 0.84,95%CI 0.54-1.31),亦无差异。在74例严重创伤性脑损伤(TBI)预设亚组中,24小时存活且无大量输血比例VHA组64% vs CCT组46%(OR 2.12,95%CI 0.84-5.34)。结论:VHA与CCT增强的大出血方案在总体结局上无差异。

要点

  • 总体人群中,VHA增强方案与CCT增强方案在24小时存活且无大量输血比例上无显著差异(VHA 67% vs CCT 64%,OR 1.15,95%CI 0.76-1.73)。
  • 28天死亡率两组无显著差异(VHA 25% vs CCT 28%,OR 0.84,95%CI 0.54-1.31)。
  • 其他次要结局及严重不良事件两组均无差异。
  • 在74例严重TBI预设亚组中,24小时存活且无大量输血比例VHA组64% vs CCT组46%(OR 2.12,95%CI 0.84-5.34),置信区间宽且跨越1。
  • 对于接受经验性大出血方案的创伤患者,VHA增强并未显示出优于CCT增强的总体获益。

适用人群与场景

  • 接受经验性大出血方案(MHP)的创伤患者。
  • 预设亚组包括严重创伤性脑损伤(TBI)患者。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及具体药物剂量或处置流程细节。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:多中心随机对照试验;样本量396例(VHA组201例,CCT组195例);人群:接受经验性MHP的创伤患者。
  • 主要终点:24小时存活且无大量输血(≥10单位红细胞)比例,VHA组67% vs CCT组64%(OR 1.15,95%CI 0.76-1.73),无显著差异。
  • 关键次要终点:28天死亡率VHA组25% vs CCT组28%(OR 0.84,95%CI 0.54-1.31),无显著差异;其他次要结局及严重不良事件无差异。
  • 预设亚组:74例严重TBI患者中,24小时存活且无大量输血比例VHA组64% vs CCT组46%(OR 2.12,95%CI 0.84-5.34)。

证据类型、等级与局限

  • 证据类型:多中心随机对照试验。
  • 原文未述局限性。

对床旁实践的改变

  • 对于接受经验性大出血方案的创伤患者,VHA增强方案相比CCT增强方案未显示总体结局获益,不能据此改变现有做法。
  • 在严重TBI亚组中观察到的差异需进一步研究验证,不能作为床旁决策依据。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

PURPOSE: Contemporary trauma resuscitation prioritizes control of bleeding and uses major haemorrhage protocols (MHPs) to prevent and treat coagulopathy. We aimed to determine whether augmenting MHPs with Viscoelastic Haemostatic Assays (VHA) would improve outcomes compared to Conventional Coagulation Tests (CCTs).

METHODS: This was a multi-centre, randomized controlled trial comparing outcomes in trauma patients who received empiric MHPs, augmented by either VHA or CCT-guided interventions. Primary outcome was the proportion of subjects who, at 24 h after injury, were alive and free of massive transfusion (10 or more red cell transfusions). Secondary outcomes included 28-day mortality. Pre-specified subgroups included patients with severe traumatic brain injury (TBI).

RESULTS: Of 396 patients in the intention to treat analysis, 201 were allocated to VHA and 195 to CCT-guided therapy. At 24 h, there was no difference in the proportion of patients who were alive and free of massive transfusion (VHA: 67%, CCT: 64%, OR 1.15, 95% CI 0.76-1.73). 28-day mortality was not different overall (VHA: 25%, CCT: 28%, OR 0.84, 95% CI 0.54-1.31), nor were there differences in other secondary outcomes or serious adverse events. In pre-specified subgroups, there were no differences in primary outcomes. In the pre-specified subgroup of 74 patients with TBI, 64% were alive and free of massive transfusion at 24 h compared to 46% in the CCT arm (OR 2.12, 95% CI 0.84-5.34).

CONCLUSION: There was no difference in overall outcomes between VHA- and CCT-augmented-major haemorrhage protocols.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Baksaas-Aasen K, Gall LS, Stensballe J, et al. Viscoelastic haemostatic assay augmented protocols for major trauma haemorrhage (ITACTIC): a randomized, controlled trial. Intensive Care Med. 2020. PMID: 33048195. doi:10.1007/s00134-020-06266-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。